

REMARKS

Claims 1-17 are cancelled. Claims 18-32 are added. It is respectfully submitted that the present response presents no new issues or new matter and places this case in condition for allowance. Reconsideration of the application in view of the above-amendments and the following remarks is requested.

I. The Rejection of Claims 1-9, 13 and 14 under 35 U.S.C. 112, Enablement

Claims 1-9, 13 and 14 are rejected under 35 U.S.C. 112, as lacking enablement. Applicants respectfully traverse the rejection.

The Examiner alleges that the claims, although enabled for methods of saccharifying starch using glucoamylase having at least 95% amino acid sequence identity to SEQ ID NO:7, the specification does not reasonably provide enablement for methods of saccharifying starch using any glucoamylase having at least 80% or 90% identity to SEQ ID NO:7. In order to expedite prosecution, the new claims refer a method using a glucoamylase which has a degree of identity of at least 95% to SEQ ID NO:7.


For the foregoing reasons, Applicants submit that the claims overcome this rejection under 35 U.S.C. 112. Applicants respectfully request reconsideration and withdrawal of the rejection.

II. Conclusion

In view of the above, it is respectfully submitted that all claims are in condition for allowance. Early action to that end is respectfully requested. The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: July 25, 2005


Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212)840-0097